Формула успешного контроля хронической обструктивной болезни легких


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Современные рекомендации по ведению больных хронической обструктивной болезнью легких (ХОБЛ) оказываются недостаточно чувствительными, чтобы обнаруживать изменения в состоянии больного ХОБЛ, которые бы свидетельствовали о будущих рисках. В статье изложена новая концепция контроля ХОБЛ, предполагающая поддержание актуального клинического статуса с наименьшим воздействием симптомов болезни в сочетании со стабильным течением, характеризующимся низким риском обострений на протяжении длительного периода времени, адаптированных к тяжести заболевания.

Полный текст

Доступ закрыт

Об авторах

А. И Синопальников

Российская медицинская академия непрерывного профессионального образования

Email: aisyn@list.ru
д.м.н., профессор, зав. кафедрой пульмонологии 125993, Россия, Москва, ул. Баррикадная, 2/1, стр. 1

Список литературы

  1. Pauwels R.A., Buist A.S., Calverley P.M., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76. Doi: 10.1164/ ajrccm.163.5.2101039.
  2. Singh D.,Agusti A.,Anzueto A., et al.Global Strategy for the Diagnosis,Management, and Prevention of Chronic Obstructive LungDisease:the GOLDscience committee report 2019. Eur Respir J. 2019;53:1900164. doi: 10.1183/13993003.00164-2019.
  3. Miravitlles M., Soler-Cataluna J.J., Myriam Calle M., et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol. 2017;53:324-35.
  4. Agusti A., MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68:687-90. Doi: 10.1136/
  5. Miravitiies M., So!er-Catauna J.J., Caiie M., eta!. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41:1252-56. doi: 10.1183/09031936.00118912.
  6. McDonald V, Higgins I., Wood L.G., et al. Multidimensional assessment, and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68:691-94. Doi: 10.1136/ thoraxjnl-2012-202646.
  7. Белоцерковская Ю.Г, Синопальников А.И., Романовских А.Г, Смирнов И.П. Концепция контроля ХОБЛ. Фарматека. 2019;26(5):17-28.
  8. Soler-Cataluna J.J., Alcazar-Navarrete B., Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397-405. doi: 10.2147/COPD.S71370.
  9. Cockcroft D.W., Swystun V.A. Asthma control versus asthma severity. J Allergy Clin Immunol. 1996;98:1016-8. doi: 10.1016/s0091- 6749(96)80185-0.
  10. Fuhlbrgge A.L. Asthma severity and asthma control: symptoms, pulmonary function, and inflammatory markers. Curr Opin Pulm Med. 2004;10:1-6. doi: 10.1097/00063198-200401000-00002.
  11. Bateman E.D., Boushey H.A., Bousquet J. et al. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med. 2004;170:836-44. doi: 10.1164/rccm.200401-033OC.
  12. Soler-Cataluna J.J., Alcazar B., Marzo M., et al. Evaluation of changes in control status in COPD: An opportunity for early intervention. Chest. 2020;157:1138-46. Doi: 10.1016/j. chest.2019.11.004.
  13. Miravitlles M, Alcazar B., Soler-Cataluna J.J. The concept of control in chronic obstructive pulmonary disease: Development of the criteria and validation for use in clinical practice. Pulmonol. 2020;30:135-41. (In Russ.).
  14. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, 2020. Available from: http://goldcopd.org/gold-2020-global-strategy-diagnosis-management-prevention-copd
  15. Celli B.R., Wedzicha J.A. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381:1257-66. Doi: 10.1056/ NEJMra1900500.
  16. Price D, Qstrem A., Thomas M., Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J COPD. 2017;12:141-68. doi: 10.2147/COPD.S116719.
  17. Miravitlles M., Baek S., Vithlani V, Lad R. Optimal bronchodilation for COPD patients: are all long-acting (32-agonist/long-acting muscarinic antagonists the same? Tuberc Respir Dis. 2018;81:198-215. doi: 10.4046/trd.2018.0040.
  18. Rodrigo G.J., Price D., Anzueto A., et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ ICS in COPD: a systematic review and meta-analysis. Int J COPD. 2017;12:907-22. doi: 10.2147/COPD. S130482.
  19. Takahashi T., Ichinose M., Inoue H., et al. Underdiagnosis and undertreatment of COPD in primary care settings. Respirol. 2003;8:504-8. doi: 10.1046/j.1440-1843.2003.00501.x.
  20. Zaas D., Wise R., Wiener C; Longcope Spirometry Investigation Team. Airway obstruction is common but unsuspected in patients admitted to a general medicine service. Chest. 2014;125:106-11. Doi: 10.1378/ chest.125.1.106.
  21. Tantucci C., Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon. Dis 2012;7:95-9. doi: 10.2147/COPD.S27480.
  22. Troosters T., Sciurba F.C., Decramer M., et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ. Prim Care Respir Med. 2014;24:14003. doi: 10.1038/npjpcrm.2014.3.
  23. Asai K., Hirata K., Hashimoto S., et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE. Respir Investig. 2016;54:428-35. doi: 10.1016/j.resinv.2016.06.006.
  24. Bateman E.D., Ferguson G.T., Barnes N., et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-94. doi: 10.1183/09031936.00200212.
  25. Wedzicha J.A., Decramer M., Ficker J.H., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet. Respir Med. 2013;1:199-209.
  26. Muro S., Yoshisue H., Kostikas K., et al. Indacaterol/ glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-nai've COPD patients: A pooled analysis. Respirol. 2020;25:393-400. doi: 10.1111/resp.13651.
  27. Wedzicha J.A., Banerji D., Chapman K.R., et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222-34. Doi: 10.1056/ NEJMoa1516385.
  28. Anzueto A.R., Kostikas K., Mezzi K., et al. Indacaterol/ glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19:121.
  29. Mammen M.J., Lloyd D.R., Kumar S., et al. Triple therapy versus dual or monotherapy with long-acting bronchodilators for COPD: A systematic review and meta-analysis. Ann Am Thorac. Soc. 2020 Jul 21. doi: 10.1513/AnnalsATS.202001-023OC.
  30. Bafadhel M., Peterson S., De Blas M.A., et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet. RespirMed. 2018;6:117-26. doi: 10.1016/S2213-2600(18)30006-7.
  31. Gibson P.G. Variability of blood eosinophils as a biomarker in asthma and COPD. Respirol. 2018;23:12-3. doi: 10.1111/resp.13200.
  32. Chen W., Thomas J., Sadatsafavi M., Fitz Gerald J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet. Respir Med. 2015;3:631-39. doi: 10.1016/S2213-2600(15)00241-6.
  33. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128:2640-46. doi: 10.1378/chest.128.4.2640.
  34. Mapel D.W., Dedrick D., Davis K. Trends and cardiovascular comorbidities of COPD patients in the Veterans Administration Medical System, 19911999. COPD. 2005;2:35-41. doi: 10.1081/copd-200050671.
  35. Sidney S., Sorel M., Quesenberry C.P, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068-75.
  36. Morgan A.D., Zakeri R., Quint J.K. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524. doi: 10.1177/1753465817750524.
  37. Morgan A.D., Zakeri R., Quint J.K. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1-16.
  38. Mannino D.M., Thorn D., Swensen A., et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962-69. doi: 10.1183/09031936.00012408.
  39. Mills N.L., Miller J.J., Anand A., et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008;63:306-11. Doi: 10.1136/ thx.2007.083493.
  40. Barr R.G., Bluemke D.A., Ahmed F.S. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362:217-27. doi: 10.1056/NEJMoa0808836.
  41. Stru B N., Bauersachs J., Welte T., Hohlfeld J.M. Left heart function in COPD. Impact of lung deflation. Herz. 2019;44(6):477-82. doi: 10.1007/s00059-019-4816-5.
  42. Alter P, Watz H., Kahnert K., et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018;137:14-22. Doi: 10.1016/j. rmed.2018.02.011.
  43. Watz H., Waschki B., Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138:32-8. doi: 10.1378/chest.09-2810.
  44. Aaron C.P, Hoffman E.A., Lima J.A.C., et al. Pulmonary vascular volume, impaired left ventricular filling and dyspnea. The MESA Lung Study. PLoSONE. 2017;12(4):e176180. doi: 10.1371/journal. pone.0176180.
  45. Cazzola M, Mantero A., Santus P, et al. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. Pulm Pharmacol Ther 2007;20:258-64. Doi: 10.1016/j. pupt.2006.02.002.
  46. Beeh K.M., Singh D., Di Scala L., et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int Herz J Chron Obstruct Pulmon Dis. 2012;7:503-13. doi: 10.2147/COPD.S32451.
  47. Beeh K.-M., Derom E., Echave-Sustaeta J., et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis. 2016;11:193-205. Doi: 10.2147/ COPD.S95055.
  48. Hohlfeld J.M., Vogel-Claussen J., Biller H., et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebocontrolled, single-centre trial. Lancet. Respir Med. 2018;6:368-78. Doi: 10.1016/ S2213-2600(18)30054-7.
  49. Vogel-Claussen J., Schonfeld C.-O., Kaireit T.F., et al. Effect of Indacaterol/Glycopyrronium on pulmonary perfusion and ventilation in Hyperinflated COPD patients (CLAIM): a double-blind, randomized, crossover trial. Am J Respir Crit Care Med. 2019;199:1086-96. doi: 10.1164/rccm.201805-0995OC.
  50. Cazzola M., Matera M.G., Donner C.F. Inhaled 2-Adrenoceptor Agonists Cardiovascular Safety in Patients with Obstructive Lung Disease. Drugs. 2005;65:1595-610. doi: 10.2165/00003495-200565120-00001.
  51. Brodde O.E. Beta1- and beta2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991; 43:203-42.
  52. Newton G.E., Parker J.D. Acute effects of beta1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-58.
  53. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309-21. doi: 10.1378/chest.125.6.2309.
  54. Sears M.R. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002;110(Suppl. 6):S322-28. doi: 10.1067/mai.2002.129966.
  55. Cazzola M., Calzetta L., Matera M.G. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf. 2010;9:783-92. doi: 10.1517/14740338.2010.500611.
  56. Yang B., Lin H., Xu C., et al. Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac m3 subtype muscarinic acetylcholine receptor. Cell Physiol Biochem. 2005;16:163-74.
  57. Shi H., Wang H., Lu Y, et al. Choline modulates cardiac membrane repolarization y activating an M3 muscarinic receptor and its coupled K+ channel. J Membr Biol. 1999;169:55-64. Doi: 10.1007/ pl00005901.
  58. Rogliani P., Calzetta L., Matera M.G., et al. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert. Opin. Pharmacother. 2019;20(6):737-50. doi: 10.1080/14656566.2019.1570133.
  59. Vestbo J., Anderson J.A., Brook R.D., et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-26. Doi: 10.1016/ S0140-6736(16)30069-1.
  60. Buhl R., Magder S., Bothner U., et al. Long-term general and cardiovascular safety of tiotropium/ olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122: 58-66. Doi: 10.1016/j. rmed.2016.11.011.
  61. Calzetta L., Matera M.G., Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95-103. Doi: 10.1016/j. coph.2018.03.011.
  62. Calzetta L., Rogliani P., Matera M.G., et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149:1181-96. Doi: 10.1016/j. chest.2016.02.646.
  63. Rogliani P, Matera M.G., Ora J., et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis. 2017;12:3469-85. doi: 10.2147/COPD.S146338.
  64. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. URL: http:// goldcopd.org/gold-reports/(accessed 14.09.2020).
  65. Chow A.H., Tong H.H., Chattopadhyay P, Shekunov B.Y Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411-37. Doi: 10.1007/ s11095-006-9174-3.
  66. Chapman K.R., Fogarty C.M., Peckitt C., et al. Delivery characteristics and patients' handling of two singledose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353-63. Doi: 10.2147/ COPD.S18529.
  67. Colthorpe P, Voshaar T., Kiekbusch T., et al. 2013. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. J Drug Assess. 2013;2:11-6. doi: 10.3109/21556660.2013.766197.
  68. Lavorini F, Fontana G.A., Usmani O.S. New inhaler devices - the good, the bad and the ugly. Respiration. 2014;88:3-15. doi: 10.1159/000363390.
  69. Molimard M., Colthorpe P Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28:219-28. Doi: 10.1089/ jamp.2014.1142.
  70. Dolovicha M.B., Kuttlerb A., Dimkeb T.J., Usmanic O.S. Biophysical model to predict lung delivery from a dual bronchodilator dry powder inhaler. Intern J Pharm. 2019;1:100018. doi: 10.1016/j.ijpx.2019.100018.
  71. Pavkov R., Mueller S., Fiebich K., et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin. 2010;26:2527-33. doi: 10.1185/03007995.2010.518916.
  72. Molimard M., Raherison C., Lignot S., et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49:1601794. doi: 10.1183/13993003.01794-2016.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2020